Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80

​Alvotech (NASDAQ:ALVO) is one of the Best Penny Stocks That Will Skyrocket. On February 5, Alvotech (NASDAQ:ALVO) announced strong initial results from a key clinical trial for AVT80. AVT80 is a potential biosimilar to the blockbuster drug, Entyvio, from Takeda.

​Management noted that the randomized, double-blind study successfully fit all primary goals, including proving AVT80 matches Entyvio’s pharmacokinetics. The trial also passed all safety, tolerability, and immune response criteria.

​“We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio, allowing us to proceed towards regulatory submissions,” noted Joseph McClellan, Chief Operating Officer.

Management also highlighted that the potential approval targets a significant market opportunity. The combined worldwide revenue for Entyvio in 2025 was roughly around $6.4 billion. Biosimilars like AVT80/AVT16 could slash costs for patients and payers once approved.

​Alvotech (NASDAQ:ALVO) is a biotechnology company specializing in the development, manufacturing, and commercialization of biosimilar medicines to provide affordable biologic alternatives globally.

While we acknowledge the potential of ALVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALVO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.